These findings provide clear evidence of SFN in the regulation of eNOS activity and NO bioavailability and suggest that it may be a promising therapeutic candidate to prevent endothelial dysfunction, atherosclerosis and other cardiovascular diseases. The gene discussed is NOS3; the disease is endothelial dysfunction.